Ranbaxy, Teva settle New York '1st-to-file pact' antitrust claims
This article was originally published in Scrip
Executive Summary
Ranbaxy and Teva will each pay $150,000 to settle charges brought by New York the generic drug makers violated antitrust laws by entering into a December 2010 pact not to challenge each other's claim of sole first-to-file exclusivity filed with the FDA for generic versions of Pfizer's cholesterol-lowering drug Lipitor (atorvastatin) and other drugs.
You may also be interested in...
Pfizer Reaches $93m Deal On Decade-Old Lipitor Antitrust Suit
An antitrust lawsuit accusing Pfizer of conspiring to delay generic competition to its Lipitor blockbuster came soon after generics entered the US market in November 2011. Only now, after a decade of back and forth, has a deal been agreed to dismiss the accusations.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.